Figure 1From: Bendamustine in patients with relapsed or refractory multiple myeloma Overall survival of 39 patients with refractory or relapsed MM treated with bendamustine and event-free survival of 21 patients with refractory or relapsed MM responding (MR+PR+CR) to bendamustine treatment.Back to article page